



STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

100 NEW YORK AVENUE, N.W. • WASHINGTON, D.C. 20005-3934

PHONE: (202) 371-2600 • FACSIMILE: (202) 371-2540 • www.skgf.com

RECEIVED

DEC 14 2001

TECH CENTER 1600/2000

JAN

5 2001

RECEIVED

ROBERT GREENE STERNE JOHN M. COVERT EDWARD W. YEE
EDWARD J. KESSLER LINDA E. ALCORN ALBERT L. FERRO*
JORGE A. GOLDSTEIN ROBERT C. MILLONIG DONALD R. BANOWIT
SAMUEL L. FOX*** MICHAEL V. MESSINGER PETER A. JACKMAN
DAVID K.S. CORNWELL JUDITH U. KIM MOLLY A. MC CALL
ROBERT W. EDMOND TIMOTHY J. SHEA, JR. TERESA U. MEDLER
TRACY-GENE G. DURKIN PATRICK E. GARRETT JEFFREY S. WEAVER
MICHELE A. CIMBALA JEFFREY T. HELVEY* KENDRICK P. PATTERSON
MICHAEL B. RAY HEIDI L. KRAUS DONALD J. FEATHERSTONE
ROBERT E. SOKOHL JEFFREY R. KURIN VINCENT L. CAPUANO
ERIC K. STEFFE PATRICK D. O'BRIEN JOHN A. HARROUN*
MICHAEL Q. LEE LAWRENCE B. BUGAISKY ALBERT J. FASULO II*
STEVEN R. LUDWIG CRYSTAL D. SAYLES ELDORA ELLISON FLOYD*

W. RUSSELL SWINDELL THOMAS C. FIALA
BRIAN J. DEL BUONO* VIRGIL L. BEASTON*
REGINALD D. LUCAS* RYAN J. STAMPER*
THEODORE A. WOOD ELIZABETH J. HAANES
ELIZABETH J. HAANES BRUCE E. CHALKER
JOSEPH S. OSTROFF KAREN R. MARKOWICZ**
SUZANNE E. ZISKA** ANDREA J. KAMAGE**

NANCY J. LEITH**
JOSEPH M. CONRAD, III*
DOUGLAS M. WILSON
ANN E. SUMMERFIELD
CYNTHIA M. BOUCHEZ
HELENE C. CARLSON
GABY L. LONGSWORTH
DUSTIN T. JOHNSON
MATTHEW J. DOWD***
AARON L. SCHWARTZ**

*LIMITED TO MATTERS
AND PROCEEDINGS BEFORE
FEDERAL COURTS & AGENCIES
**REGISTERED PATENT AGENT
***SENIOR COUNSEL

December 12, 2001

WRITER'S DIRECT NUMBER:
(202) 789-5525
INTERNET ADDRESS:
BRIAND@SKGF.COM

Commissioner for Patents
Washington, D.C. 20231

Attn: Art Unit 1645

Re: U.S. Utility Continuation Patent Application
(Based on PCT/GB99/04162)
Appl. No. 09/877,244; Filed: June 11, 2001
For: **Use of Vascular Endothelial Growth Factor (VEGF)**
Inventors: STADDON *et al.*
Our Ref: 0623.1090001/EKS/BJD

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. 24 pages of Form PTO-1449 citing 78 documents;
3. A copy of each of the 78 cited documents; and
4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
December 12, 2001
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

BJD/nef
Enclosures

P:\USERS\BRIAND\0623\1090001\121501,IDS cvr.wpd
SKGF Rev. 11/01/01 mac



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Staddon *et al.*

Appl. No. 09/877,244

Filed: June 11, 2001

For: **Use of Vascular Endothelial
Growth Factor (VEGF)**

Confirmation No. 9543

DEC 14 2001

Art Unit: 1645

TECH CENTER 1600/2900

Examiner: *To be assigned*

Atty. Docket: 0623.1090001/EKS/BJD

TECH CENTER 1600/2900
JAN 15 2001

Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of these documents is provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Document AM1, Japan Patent Office Publication No. 4-13631, assigned to Tonen Corporation and Eisai KK, appears to disclose the purification and characterization of a substance from *Anacardium occidentale* that has tyrosine kinase-inhibiting activity and that may be useful in treating or preventing cancer metastasis. A copy of an unverified abstract of this publication in the English language (from Derwent WPI) is included herewith as Reference Number AS24.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Brian J. Del Buono
Attorney for Applicants
Registration No. 42,473

Date: Dec. 12, 2001

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600